Lowering The 52 Week Low, Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) Finishing At $1.95

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)

December 18th, 2018
With markets going up Achillion Pharmaceuticals, Inc. finished Tuesday’s trading session down 18.75%, a $0.45 decrease to close on $1.95. As well as the drop in value, Achillion Pharmaceuticals, Inc. hit a new 52 week low of $1.90, breaking the previous low of $2.33 from earlier this October. Achillion Pharmaceuticals, Inc. swung 34.74% between high and low. Despite the drop in value, trading volumes were solid at 508% of normal which can indicate investor opportunities.

ACHN was outperformed by the rest of the Healthcare sector which went down only 0.80%.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Consumer Discretionary saw the biggest increase of the day (1.03%), while Energy saw the biggest drop (2.35%). Healthcare has seen the biggest year-to-date gain at 5.09%. The biggest loss this year has been the Materials sector declining 17%.

Consumer Discretionary saw the biggest turnaround from its 5-day performance of -4.12%, as it went up 1.03%.

Sector Breakdown

  • Consumer Discretionary went up with a 1.03% change.
  • Real Estate went up with a 0.95% change.
  • Information Technology went up with a 0.86% change.
  • Communication Services went up with a 0.62% change.
  • Industrials went up with a 0.58% change.
  • Materials went up with a 0.56% change.
  • Financials went down with a -0.48% change.
  • Utilities went down with a -0.64% change.
  • Healthcare went down with a -0.80% change.
  • Consumer Staples went down with a -1.17% change.
  • Energy went down with a -2.35% change.

Achillion Pharmaceuticals, Inc. Info

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

All amounts in USD unless otherwise indicated
ACHN daily update

ACHN daily update
ACHN daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.